Wegovy

Adjunct to reduced-calorie diet & increased physical activity for wt management, including wt loss & maintenance, in adults w/ initial BMI of ≥30 kg/m² (obese), or ≥27 to <30 kg/m² (overwt) in the presence of at least 1 wt-related comorbidity eg, dysglycaemia (prediabetes or type 2 DM), HTN, dyslipidaemia, obstructive sleep apnoea or CV disease. Adjunct to reduced-calorie diet & increased physical activity for wt management in adolescents ≥12 yr w/ obesity (BMI ≥95th percentile) as defined on sex- & age-specific BMI growth charts, & body wt >60 kg.

SC Adult & adolescent ≥12 yr Initially 0.25 mg once wkly on wk 1-4. Escalate to 0.5 mg once wkly on wk 5-8, then 1 mg once wkly on wk 9-12, then 1.7 mg once wkly on wk 13-16. Maintenance dose: 2.4 mg once wkly. There should be at least 3 days (>72 hr) between 2 doses.

May be taken with or without food.

Hypersensitivity.

Wkly doses >2.4 mg are not recommended. Should not be administered intravenously or intramuscularly. Increased risk of residual gastric content due to delayed gastric emptying should be considered prior to performing procedures w/ general anaesth or deep sedation. Potential risk of dehydration in relation to GI side effects. Discontinue treatment if pancreatitis is suspected & do not restart if confirmed. Caution in patients w/ history of pancreatitis. Should not be used as substitute for insulin in patients w/ type 2 diabetes. Reports of diabetic ketoacidosis in insulin-dependent patients after rapid discontinuation or dose reduction of insulin when treatment w/ GLP-1 receptor agonist is started. Should not be used in combination w/ other GLP-1 receptor agonist products. Combination w/ sulfonylurea or insulin may increase risk of hypoglycaemia in patients w/ type 2 diabetes. Not recommended in patients w/ type 2 diabetes w/ uncontrolled or potentially unstable diabetic retinopathy. Driving or use of machines should be done cautiously if dizziness occurs. Precautions should be taken to avoid hypoglycaemia while driving & using machines. Not recommended in patients treated w/ other products for wt management; patients w/ type 1 diabetes; patients w/ CHF NYHA class IV; patients w/ severe renal impairment (eGFR <30 mL/min/1.73 m²) including ESRD; patients w/ severe hepatic impairment. Caution in patients w/ inflammatory bowel disease; patients w/ diabetic gastroparesis; patients w/ mild or moderate hepatic impairment; elderly ≥85 yr. Women of childbearing potential should use contraception while on semaglutide treatment. Should not be used during pregnancy & breast-feeding. Should be discontinued at least 2 mth before a planned pregnancy. Safety & efficacy in childn <12 yr have not been established. Discontinue & re-evaluate treatment if adolescent patients have not reduced their BMI by at least 5% after 12 wk on the 2.4 mg or max tolerated dose.

Headache; vomiting, diarrhoea, constipation, nausea, abdominal pain; fatigue. Hypoglycaemia (in patients w/ type 2 diabetes); dizziness, dysgeusia, dysaesthesia; diabetic retinopathy (in patients w/ type 2 diabetes); gastritis, GERD, dyspepsia, eructation, flatulence, abdominal distension; cholelithiasis; hair loss; inj site reactions.

Could potentially influence absorption of concomitantly administered oral medicinal products that require rapid GI absorption.

Anti-Obesity Agents / Antidiabetic Agents

A10BJ06 - semaglutide ; Belongs to the class of glucagon-like peptide-1 (GLP-1) analogues. Used in the treatment of diabetes.

P₁S₁S₃